Oxytocin-S, 10 iu/ml, Solution for Injection

País: Reino Unido

Idioma: inglés

Fuente: VMD (Veterinary Medicines Directorate)

Ingredientes activos:

Oxytocin Synthetic

Disponible desde:

MSD Animal Health UK Limited

Código ATC:

QH01BB02

Designación común internacional (DCI):

Oxytocin Synthetic

formulario farmacéutico:

Solution for injection

tipo de receta:

POM-V - Prescription Only Medicine – Veterinarian

Grupo terapéutico:

Cats, Cattle, Dogs, Goats, Horses, Pigs, Sheep

Área terapéutica:

Hormone

Estado de Autorización:

Authorized

Fecha de autorización:

1994-07-29

Ficha técnica

Revised: December 2020
AN: 01394/2020
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Oxytocin-S, 10 iu/ml, solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
Active substance:
Oxytocin 10 iu
(equivalent to 0.018 mg oxytocin)
Excipients:
Chlorbutanol 5 mg
(Added as Chlorbutanol hemihydrate 5.254 mg as a preservative)
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for Injection
Clear aqueous solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle, horses, pigs, sheep, goats, cats and dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Injections with this product will initiate strong, regular and
purposeful
contractions of the uterine muscle especially in the later stages of
pregnancy
and post-partum. It also evokes the 'let-down' of milk although it has
no action
on the smooth muscles of the gut or urinary bladder, nor is it
effective in the
treatment of diabetes insipidus. The absence of vasopressor and
antidiuretic
effects make it particularly suitable for obstetric use (stimulation
of parturition,
promotion of uterine involution and control of post-partum
haemorrhage) and
the treatment of agalactia.
The product is indicated for:
-
stimulation of uterine contraction to facilitate parturition in the
presence of a
fully dilated cervix
-
to promote involution of the post-parturient uterus and thus aid the
passage of
retained placenta
-
to aid in control of post-partum haemorrhage
-
promotion of milk 'let-down' in cases of agalactia and to facilitate
‘stripping
out’ of infected quarters in the treatment of mastitis in cows.
Revised: December 2020
AN: 01394/2020
Page 2 of 5
4.3
CONTRAINDICATIONS
1.
When the product is used as an aid to parturition, cervical dilation
must
be confirmed prior to administration to prevent the risk of foetal
death
and possible uterine rupture.
2.
The product is contraindicated in any form of obstructive dystocia.
3.
Excessive doses of the product may delay parturi